NIHR UCLH Biomedical Research Centre
banner
uclhresearch.bsky.social
NIHR UCLH Biomedical Research Centre
@uclhresearch.bsky.social
NIHR University College London Hospitals Biomedical Research Centre is part of @nihr.bsky.social and is a partnership between UCLH and UCL to develop experimental medicine.
A new daily pill, baxdrostat, has shown sustained 24 hour blood pressure control - including at night, when heart attack and stroke risk is highest.

The global Bax24 trial was led by Professor Bryan Williams, @ucl.ac.uk, and supported by the @nihr.bsky.social Biomedical Research Centre at UCLH.
New drug offers 24-hour control for hard-to-treat high blood pressure
A new daily pill has shown continuous, round-the-clock control of high blood pressure in people whose condition is difficult to manage, according to a global study led by Professor Bryan Williams, UCL...
www.uclhospitals.brc.nihr.ac.uk
November 10, 2025 at 1:01 PM
A new @ucl.ac.uk -led analysis of the PANDA trial (2019) has found that sertraline, one of the most commonly prescribed antidepressants, improves core emotional symptoms of depression within two weeks.

The PANDA trial was developed in collaboration with the UCLH Joint Research Office.
Antidepressants improve core depressive symptoms early on
One of the most common antidepressants, sertraline, contributes to a modest improvement in core depression and anxiety symptoms, including low mood, within two weeks, finds a new analysis of a major c...
www.uclhospitals.brc.nihr.ac.uk
November 3, 2025 at 2:24 PM
Researchers at @uclh.bsky.social have recruited the first UK participant to BEHOLD-2, a global trial testing a novel anti-cancer treatment combination for advanced solid tumours including endometrial & ovarian cancer.

The trial is delivered via the @nihr.bsky.social UCLH Clinical Research Facility.
First participant in the UK recruited for new trial of advanced solid tumours
UCLH has recruited the first participant in the UK for a study testing a new anti-cancer treatment combination for advanced solid tumours such as endometrial and ovarian cancers. This global study, ta...
www.uclhospitals.brc.nihr.ac.uk
October 31, 2025 at 1:04 PM
A UK first: a patient with multiple sclerosis has received CAR T-cell therapy in a trial testing whether this personalised treatment could slow or even halt disease progression.

“Our ultimate goal is to achieve long periods of remission with a single, one-time CAR T treatment.” - Dr Claire Roddie
First MS patient in the UK to trial CAR T cell therapy at UCLH
A UK patient with multiple sclerosis (MS) is the first to receive CAR T cell therapy in a BRC supported trial testing whether this personalised treatment may slow or even halt the progression of the d...
www.uclhospitals.brc.nihr.ac.uk
October 24, 2025 at 9:26 AM
💊 The world’s largest-ever clinical trial to slow or stop Parkinson’s disease has launched - led by @ucl.ac.uk and @newcastleuni.bsky.social.

The £26M project will test multiple potential Parkinson’s treatments in parallel - cutting years off drug testing and transforming how we treat Parkinson’s.
Largest-ever Parkinson’s disease trial opens across UK
The world’s largest-ever clinical trial of treatments to slow or stop the progression of Parkinson’s disease has launched, led by researchers at UCL and Newcastle University.The £26 million project is...
www.uclhospitals.brc.nihr.ac.uk
October 16, 2025 at 1:03 PM
🧠 Researchers @ucl.ac.uk have found a way to make MRI scans for dementia up to 3x faster.

Their new 'parallel imaging' approach could boost diagnosis rates by doubling daily capacity for tests, providing a future where all patients have access to technology for fast and accurate diagnosis.
Faster MRI scans offer new hope for dementia diagnosis
A UCL study shows it is possible to cut the time for diagnostic MRI scans for dementia to one third of their standard length.Shorter scans would be easier and more comfortable for patients and also me...
www.uclhospitals.brc.nihr.ac.uk
October 14, 2025 at 1:42 PM
📼 Watch UCLH's new film that seeks to support members of Black communities who want to take part in health research.

The film shares stories from people involved in the @nihr.bsky.social Improving Black Health Outcomes theme, highlighting why they joined and what representation means in research.
IBHO BioResource and sickle cell
YouTube video by NIHR BioResource
www.youtube.com
October 8, 2025 at 2:04 PM
💡 A new gene therapy for Huntington’s disease, AMT-130, has shown it can significantly slow disease progression by 75% over 3 years.

The phase I/II study, led by @ucl.ac.uk researchers and taking place at @uclh.bsky.social and other sites, offers new hope for families affected by this disease.
Huntington’s Disease gene therapy shows 75 per cent slowing of disease progression
A new gene therapy to treat Huntington’s disease known as AMT-130 has shown positive data from a study which is being run at UCLH and other sites.The phase I/II study demonstrates a statistically sign...
www.uclhospitals.brc.nihr.ac.uk
September 25, 2025 at 11:41 AM
🧠 New analysis in @thelancet.com has shown, for the first time, that Alzheimer’s drugs lecanemab and donanemab can slow disease progression.

The anti-amyloid antibody medications allow patients to preserve functional independence.

@uclh.bsky.social @ucl.ac.uk @uclbrainscience.bsky.social
New medications for Alzheimer’s disease comparable in effectiveness to approved drugs in cancer, MS and arthritis
New medications for Alzheimer’s disease – which are not yet approved in some countries – have shown for the first time that clinical decline can be slowed with comparable effectiveness to approved med...
www.uclhospitals.brc.nihr.ac.uk
September 24, 2025 at 2:21 PM
Last chance to register - deadline tomorrow ⏰

Join our online workshop 'Intro to PPI & Ethical Considerations'

📅 Thursday 25 Sept, 10am-12:30pm

The workshop will cover:
- Why PPI matters in research
- Practical approaches to involvement
- Ethical principals
PPI Training | UCLH Biomedical Research Centre
www.uclhospitals.brc.nihr.ac.uk
September 17, 2025 at 11:19 AM
🏆 Huge congratulations to the Cancer Clinical Trials Unit (CCTU) at @uclh.bsky.social on winning the Contribution to World Class Research Award at the University College London Hospitals NHS Foundation Trust Celebrating Excellence Awards 2025.
September 15, 2025 at 11:40 AM
A @ucl.ac.uk-led trial is investigating a simple blood test that could transform how Alzheimer’s disease is diagnosed.

The ADAPT study aims to demonstrate that measuring protein (p-tau217) levels can deliver earlier, fairer access to diagnosis & future NHS treatments.
UK trial launches to transform Alzheimer’s diagnosis with simple blood test
A major trial supported by the BRC aims to transform the diagnosis of Alzheimer’s disease through a simple blood test.The UCL-led trial is now welcoming its first participants who will be recruited vi...
www.uclhospitals.brc.nihr.ac.uk
September 11, 2025 at 12:37 PM
🔬 Major UK trial, published in @thelancet.com, finds sinus surgery is more effective than antibiotics for chronic rhinosinusitis (CRS).

The trial was led by @ucl.ac.uk alongside academics from @uniofeastanglia.bsky.social and Guy’s and St Thomas’ NHS Foundation Trust.
Surgery to treat chronic sinus disease more effective than antibiotics
Sinus surgery is more effective than antibiotics at treating chronic rhinosinusitis, according to a major clinical trial led by UCL along with academics at the University of East Anglia and Guy’s and ...
www.uclhospitals.brc.nihr.ac.uk
September 7, 2025 at 12:10 PM
💊 A once-daily tablet, baxdrostat, has been shown to significantly lower blood pressure in patients whose blood pressure remains high despite taking several existing medicines.

Results are from the global BaxHTN trial, led by @ucl.ac.uk's Professor Bryan Williams.
Promising new drug for people with stubborn high blood pressure
A new treatment has been shown to significantly lower blood pressure in people whose levels stays dangerously high, despite taking several existing medicines, according to the results of a Phase III c...
www.uclhospitals.brc.nihr.ac.uk
September 3, 2025 at 12:24 PM
Reposted by NIHR UCLH Biomedical Research Centre
Sinus surgery is more effective than antibiotics at treating chronic rhinosinusitis, finds a major clinical trial led by @uclbrainscience.bsky.social @uclhresearch.bsky.social with academics at @uniofeastanglia.bsky.social and Guy’s and St Thomas’ in @thelancet.com, with @nihr.bsky.social funding
Surgery to treat chronic sinus disease more effective than antibiotics
Sinus surgery is more effective than antibiotics at treating chronic rhinosinusitis, according to a major clinical trial led by UCL along with academics at the University of East Anglia and Guy’s and ...
www.ucl.ac.uk
August 29, 2025 at 4:00 PM
📃 Check out page 29 of the NIHR 2024/25 Annual Report for a feature on new cancer immunotherapy trials at @uclh.bsky.social - supported by our Biomedical Research Centre & Clinical Research Facility.

www.nihr.ac.uk/about-us/who...
www.nihr.ac.uk
August 27, 2025 at 10:50 AM
New to Patient and Public Involvement (PPI)?

Join our 'Intro to PPI and Ethical Considerations' workshop, designed for anyone looking to understand the foundations of meaningful patient engagement in research.

📅 25 September, 10am to 12.30pm
💻 Online
Sign up now ⬇️
PPI Training | UCLH Biomedical Research Centre
www.uclhospitals.brc.nihr.ac.uk
August 26, 2025 at 11:57 AM
🍽️ A new clinical trial, led by clinicians at UCL and UCLH, suggests eating less processed food could help sustain a healthy weight long term.

When given nutritionally matched diets, trial participants lost twice as much weight eating minimally processed vs ultra-processed foods.
Less processed diet may be more beneficial for weight loss
When given nutritionally matched diets, participants lost twice as much weight eating minimally processed foods compared to ultra-processed foods, suggesting that cutting down on processing could help...
www.uclhospitals.brc.nihr.ac.uk
August 21, 2025 at 11:18 AM
A UCL & UCLH-led study has shown that prostate cancer patients with certain molecular features respond better to immunotherapy than previously thought.

The multicentre NEPTUNES trial suggests treatment with immunotherapies (nivolumab & ipilimumab) could benefit ~25% of patients with this cancer.
New hope that immunotherapy can be effective for some prostate cancer patients
Response rates to immunotherapy treatment for prostate cancer patients improves markedly when specific molecular features of the tumour are selected for, compared to trials in unselected patients, sho...
www.uclhospitals.brc.nihr.ac.uk
August 20, 2025 at 2:26 PM